ALEXANDRIA, Va., June 6 -- United States Patent no. 12,281,147, issued on April 22, was assigned to A-Alpha Bio Inc. (Seattle).

"Interleukin 21 variants" was invented by Davis Goodnight (Seattle), Emily Engelhart (Seattle) and Ryan Swanson (Seattle).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides interleukin 21 (IL-21) variants that have (i) decreased or no binding to a human interleukin 21 receptor (IL-21R) as compared to a wild-type human IL-21 polypeptide; or (ii) increased stability as compared to a wild-type human IL-21 polypeptide; or (iii) decreased or no binding to a human interleukin 21 receptor (IL-21R) as compared to a wild-type human IL-21 polypeptide and increased stability...